Belvedere Trading
ABCL icon

Belvedere Trading’s AbCellera Biologics ABCL Stock Holding History

Belvedere Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,861
Closed -$16.9K – 876
2022
Q4 		$18.9K Buy
+1,861
New +$21.5K ﹤0.01% 834
2022
Q2 		– Sell
-19,810
Closed -$172K – 353
2022
Q1 		$172K Buy
+19,810
New +$188K ﹤0.01% 262

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Belvedere Trading's ABCL Position: Q1 2023 in Review

Belvedere Trading sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 1,861 shares — an estimated $16.9K sold.

Belvedere Trading first reported a position in ABCL in Q1 2022 and held it in 2 quarters. The position peaked at $172K in Q1 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Belvedere Trading reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,861 AbCellera Biologics shares in Q1 2023, an estimated $16.9K.
  • Belvedere Trading first reported a position in AbCellera Biologics in Q1 2022 and held it in 2 quarters.
  • Belvedere Trading's AbCellera Biologics position peaked at $172K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.